MRNA

Moderna
D

MRNA

246.890
USD
-3.92
(-1.56%)
Pre Open·252.480USD+5.590(+2.26%)
Last updated: · Delayed 15 min
Q4 FY2026 · Earnings report
EPS estimate -2.01Revenue estimate 556.40M
OverviewFinancialsSignalsForecastEarningsCompany

Moderna revenue 2016–2026

Moderna's revenue in Q3 FY2026, the three months to 30 September 2026, was 1.31B USD, up 29.2% on the same quarter a year before. Moderna's revenue over the last twelve months was 2.53B USD, up 13.7% on the twelve months before. In fiscal year 2025 it was 1.94B USD, down 39.2% on the year before.

Last updated 6 Nov 2026 · Next report 12 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 20262.53B+13.69%707.00M-2.79B
FY202531 Dec 20251.94B-39.23%1.08B-2.82B
FY202431 Dec 20243.20B-53.29%1.74B-3.56B
FY202331 Dec 20236.85B-63.72%2.16B-4.71B
FY202231 Dec 202218.88B+6.42%13.46B8.36B
FY202131 Dec 202117.74B+2,107.63%15.12B12.20B
FY202031 Dec 2020803.40M+1,234.34%764.21M-747.06M
FY201931 Dec 201960.21M-55.42%29.19M-514.02M
FY201831 Dec 2018135.07M-34.38%110.21M-384.73M
FY201731 Dec 2017205.83M+89.88%185.29M-255.92M
FY201631 Dec 2016108.40M—93.28M-216.21M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Moderna revenue growth by segment

Q2 FY2026 against Q2 FY2025

Product Sales171.00M
-2.8%

Moderna revenue by segment over time

COVID Stand-ready manufacturing revenue Grant revenue Collaboration revenue Licensing and royalty revenue RSV Messenger RNA (mRNA) Medicines Product Sales
Fiscal yearCOVIDStand-ready manufacturing revenueGrant revenueCollaboration revenueLicensing and royalty revenueRSVMessenger RNA (mRNA) MedicinesProduct Sales
FY20251.81B 80.00M 22.00M -40.5%13.00M +8.3%11.00M 8.00M — —
FY2024— — 37.00M 12.00M — — — 4.52B
FY2023— — — — — — 6.85B -64.4%—
FY2022— — — — — — 19.26B +4.3%—
FY2021— — — — — — 18.47B +2,199.1%—
FY2020— — — — — — 803.40M +1,234.3%—
FY2019— — — — — — 60.21M -55.4%—
FY2018— — — — — — 135.07M —

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Moderna's revenue

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.